The BIOSECURE provisions, signed into US law in December 2025, will restrict US federal agencies, contractors and grant recipients from using biotechnology equipment and services from designated “companies of concern.” Many drug developers are already reviewing their supply chains in response, and India’s contract development and manufacturing organisations (CDMOs) are among the obvious alternatives. Winning that work depends less on the law than on capacity: audit-ready facilities, available quickly, in the right technologies.
What does the law actually do?
The BIOSECURE provisions were included in the US National Defense Authorization Act for fiscal year 2026, signed on 18 December 2025. In outline:
- Federal agencies, federal contractors and recipients of federal grants and loans will be restricted from procuring or using biotechnology equipment or services from “biotechnology companies of concern.”
- Companies of concern include entities on a US Department of Defense list and others designated through a process led by the Office of Management and Budget, which must publish an initial list within a year.
- Prohibitions phase in after implementing guidance and procurement rule changes, with a five-year grandfathering period for certain existing contracts.
The final law does not name specific companies in its text, so the list itself is still to come. But drug developers rarely wait for the last day. Supply chain changes in pharma take years, so many start early.
Why does this matter for India?
India already supplies a large share of the world’s generic medicines and has deep chemistry and manufacturing talent. When developers look to diversify, India is high on the list.
The catch is that diversification needs space that is ready now. A sponsor moving a program wants a partner who can start tech transfer within months, not one who will break ground next year. That makes facility capacity, especially in biologics and complex modalities, the real bottleneck.
What do sponsors look for in a CDMO facility?
| What Sponsors Check | Why It Matters | What the Building Contributes |
|---|---|---|
| Regulatory Track Record | US and EU inspection history shapes risk | Layouts and flows designed for inspection readiness |
| Data Integrity | Recent warning letters often cite data issues | Validated monitoring systems, controlled access, audit trails |
| Technology Fit | Biologics, peptides, ADCs, and cell therapy need different suites | Flexible shell spaces that can host different modalities |
| Available Capacity | Programs move when space is ready | Ready modules and quick build-out capabilities |
| Segregation and Containment | Multi-client sites need cross-contamination control | Dedicated HVAC, segregated suites, containment where needed |
| Business Continuity | Supply cannot stop | Reliable power, utilities, redundancy, and backup systems |
Notice how many of these come down to infrastructure. Data integrity sounds like a software issue, but environmental monitoring that is validated, continuous and exportable starts with the building systems.
How fast can new CDMO capacity come online?
That depends on the starting point. Building on bare land takes longest, because design, approvals, construction and qualification run in sequence. Starting in a GMP-ready shell, where HVAC, utilities and monitoring are already in place, shortens the build. Plug-and-play suites shorten it further for development-stage work.
For CDMOs, speed matters twice: first to secure a sponsor’s program, then to keep it on schedule.
What should a CDMO check before expanding?
- Which modalities sponsors are asking for most
- Whether existing sites have room, or a new campus is faster
- GMP-ready shells or modules available near current talent
- Validated environmental monitoring that supports data integrity
- Segregation options for multi-client work
- Containment capability for potent compounds
- Utilities and backup that meet sponsor continuity expectations
Where does a science campus fit?
A CDMO that needs to add capacity quickly gains a lot from a campus that already runs the utility backbone and monitoring systems sponsors will audit.
NQF Hubs (NXT QST FWD) provides GMP-ready manufacturing modules, plug-and-play labs, built-to-suit facilities and build-outs with GMP qualification support, plus central BMS/EMS integration, as set out on its Solutions page. Our guides to biosimilar manufacturing facilities and peptide manufacturing cover two modalities sponsors are actively moving.
Frequently asked questions
What is the BIOSECURE Act?
It is a set of US provisions, enacted in the FY2026 National Defense Authorization Act in December 2025, restricting federal agencies, contractors and grantees from using biotechnology equipment and services from designated companies of concern.
When do BIOSECURE restrictions take effect?
They phase in after the US publishes a list of companies of concern, issues guidance and revises procurement rules, with a five-year grandfathering period for certain existing contracts.
How could BIOSECURE affect Indian CDMOs?
Drug developers reviewing their supply chains may move work to alternative partners, and Indian CDMOs are among the main candidates, provided they have audit-ready capacity available.
What do sponsors look for in a CDMO facility?
A strong regulatory track record, data integrity, the right technology, available capacity, segregation for multi-client work and reliable utilities.
Adding CDMO capacity? Talk to NQF Hubs about GMP-ready and built-to-suit space. Get in touch
6. External sources cited
- Mondaq, “Final FY 2026 NDAA includes BIOSECURE provisions and new opportunities for biotech as DoD national security priority”: https://www.mondaq.com/unitedstates/life-sciences-biotechnology-nanotechnology/1725474/final-fy-2026-ndaa-includes-biosecure-provisions-and-new-opportunities-for-biotech-as-dod-national-security-priority
- Goodwin, “BIOSECURE Act included in final draft NDAA compromise text” (7 Dec 2025): https://www.goodwinlaw.com/en/insights/publications/2025/12/alerts-lifesciences-biosecure-act-included-in-final-draft-ndaa-compromise-text